Diamyd Reports Promising Safety Findings from Phase I Study in Chronic Pain
To date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States."The Phase I trial is validating the safety of our entire neurology platform. That no drug related Serious Adverse Events have been observed strengthens our confidence in the platform and the potential it has in cancer pain and other